1802650-31-2
Chemical Structure
ZY-444
- CAS No.: 1802650-31-2
- Formula:C26H28N4OS
- Molecular Weight:444.59
IUPAC Name: N4-((5-(4-(benzyloxy)phenyl)thiophen-2-yl)methyl)-N2-isobutylpyrimidine-2,4-diamine
InChIKey: ROSPRUQNDJIWDD-UHFFFAOYSA-N
SMILES: CC(C)CNC1=NC=CC(NCC2=CC=C(C3=CC=C(OCC4=CC=CC=C4)C=C3)S2)=N1
Biological Activity: ZY-444 is an anti-cancer agent, targeting pyruvate carboxylase (PC). ZY-444 suppresses the Wnt/β-catenin/Snail signaling pathway by blocking nuclear translocation of β-catenin. ZY-444 selectively inhibits proliferation, migration, and invasion and induces apoptosis in cancer cells. ZY-444 exhibits potent anti-tumor in cancer mouse models. ZY-444 can be used for the study of breast cancer, lung cancer (NSCLC), prostate cancer and iodine-refractory thyroid cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ZY-444 | 99.51% | ZY-444 is an anti-cancer agent, targeting pyruvate carboxylase (PC). ZY-444 suppresses the Wnt/β-catenin/Snail signaling pathway by blocking nuclear translocation of β-catenin. ZY-444 selectively inhibits proliferation, migration, and invasion and induces apoptosis in cancer cells. ZY-444 exhibits potent anti-tumor in cancer mouse models. ZY-444 can be used for the study of breast cancer, lung cancer (NSCLC), prostate cancer and iodine-refractory thyroid cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lin Q, et al. Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Breast Cancer Progression. Adv Sci (Weinh). 2020 Mar 12;7(9):1903483. [Content Brief]
- [2]. Han MT, et al. ZY-444 inhibits the growth and metastasis of prostate cancer by targeting TNFAIP3 through TNF signaling pathway. Am J Cancer Res. 2023 Apr 15;13(4):1533-1546. [Content Brief]
- [3]. Liu Y, et al. Pyruvate carboxylase promotes malignant transformation of papillary thyroid carcinoma and reduces iodine uptake. Cell Death Discov. 2022 Oct 20;8(1):423. [Content Brief]
Keywords
